KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

In the KEYNOTE-811 trial, the KEYTRUDA regimen demonstrated a statistically significant PFS improvement in advanced HER2-positive gastric or GEJ adenocarcinoma in tumors expressing PD-L1 compared to...

Related Keywords

Canada ,United States ,Yelenay Janjigian , ,Linkedin ,Merck Co Inc ,European Commission ,Exchange Commission ,Drug Administration ,Memorial Sloan Kettering Cancer Center ,Youtube ,Statement Of Merck Co Inc ,Twitter ,European Society For Medical Oncology ,Merck Research Laboratories ,Facebook ,Instagram ,European Society ,Medical Oncology ,Combined Positive Score ,Chief Attending Physician ,Gastrointestinal Oncology ,Principal Investigator ,Marjorie Green ,Merck Research ,Neck Squamous Cell ,Bacillus Calmette Guerin ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Markets ,